You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent anticancer agent that blocks DNA synthesis. Induces apoptosis via p53-dependent and -independent mechanisms. Inhibits X-linked inhibitor of apoptosis protein (XIAP) expression and activates caspase-3. In certain glioma cell lines, sensitizes cells to TNF-α-induced apoptosis.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||1.5||5 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 300.05. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.05 mM||66.66 mL||333.28 mL||666.56 mL|
|0.25 mM||13.33 mL||66.66 mL||133.31 mL|
|0.5 mM||6.67 mL||33.33 mL||66.66 mL|
|2.5 mM||1.33 mL||6.67 mL||13.33 mL|
References are publications that support the biological activity of the product.
Seki et al (2000) Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother.Pharmacol. 45 199 PMID: 10663637
Duan et al (2004) Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisp. and tumor necrosis factor α. Clin.Cancer Res. 10 234 PMID: 14734475
Nomura et al (2004) Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells. Urol.Oncology 22 453
If you know of a relevant reference for Cisplatin, please let us know.
View Related Products by Product Action
Keywords: Cisplatin, Cisplatin supplier, Potent, proapoptotic, anticancer, agent, activates, caspase-3, DNA-alkylating, antitumor, Caspases, Apoptosis, Inducers, Proteinases, Proteases, chemotherapeutics, CDDP, 2251, Tocris Bioscience
25 Citations for Cisplatin
Citations are publications that use Tocris products. Selected citations for Cisplatin include:
Xiao et al (2019) TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC. Cancers (Basel) 11 PMID: 31443242
Saja et al (2015) Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1(low) Monocytes. Cell Death Dis 12 1802 PMID: 26344769
Sun et al (2015) SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Korean J Pain 6 e1990 PMID: 26583330
Lin et al (2015) A New Rat Model of Cisplatin-induced Neuropathic Pain. Oncotarget 28 236 PMID: 26495078
Kathawala et al (2014) Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated PacT. resistance: a preclinical study. Mol Cancer Ther 13 714 PMID: 24431074
Kathawala et al (2014) Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Int J Oncol 44 1634 PMID: 24626598
Guindon et al (2014) Optimization of a cisp. model of chemotherapy-induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status. Mol Pain 10 56 PMID: 25189223
Kim et al (2016) Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer 16 678 PMID: 27558154
Ibáñez et al (2012) A high throughput scintillation proximity imaging assay for protein methyltransferases. Comb Chem High Throughput Screen 15 359 PMID: 22256970
Natrajan et al (2012) Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res 14 R53 PMID: 22433433
Chia et al (2017) Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun 8 435 PMID: 28874669
Marcus et al (2015) Tolerance to the antinociceptive effects of chronic mor. requires c-Jun N-terminal kinase. Mol Pain 11 34 PMID: 26065412
Su et al (2019) Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance. Oncogene 38 1979 PMID: 30361686
Zhang (2017) The BTK Inhibitor, Ibrutinib (PCI-32765) Overcomes PacT. Resistance in ABCB1 and ABCC10 Overexpressing Cells and Tumors. Mol Cancer Ther 16 1021 PMID: 28265007
Guindon et al (2013) Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following c Pharmacol Res 67 94 PMID: 23127915
Robinson et al (2013) RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One 8 e78641 PMID: 24265703
Fard et al (2013) The heterogenic final cell cycle of chicken retinal Lim1 horizontal cells is not regulated by the DNA damage response pathway. Cell Cycle 13 408 PMID: 24247150
Deng et al (2012) The maintenance of cisplatin- and PacT.-induced mechanical and cold allodynia is suppressed by cannabinoid CB? receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 8 71 PMID: 22998838
Deng et al (2017) Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture. J Pharmacol Exp Ther 360 215 PMID: 27821713
Florea et al (2017) Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma. Oncotarget 8 22876 PMID: 28206967
Brown et al (2017) TGF-β-Induced Quiescence Mediates Chemoresistance of Tumor-Propagating Cells in Squamous Cell Carcinoma. Cell Stem Cell 21 650 PMID: 29100014
Kathawala et al (2015) The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated PacT. resistance: a preclinical and pharmacokinetic study. Oncotarget 6 510 PMID: 25402202
Liu and Kwiatkowski (2015) Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. Mol Cancer Ther 14 174 PMID: 25349305
Szabova et al (2014) Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. Cell Rep 9 e95649 PMID: 24748377
Fedoseienko et al (2016) Nuclear COMMD1 Is Associated with CDDP Sensitivity in Ovarian Cancer. PLoS One 11 e0165385 PMID: 27788210
Do you know of a great paper that uses Cisplatin from Tocris? Please let us know.
Reviews for Cisplatin
Average Rating: 5 (Based on 5 Reviews.)
Have you used Cisplatin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
B16F10 Cell were treated with 200 mM of Cisplatin for 18 hours and Cells viability was assessed using Flowcytometery
Administration in mice chemotherapy-induced-peripheral neuropathy model. Cisplatin (2.3mg/kg) dissolved in sterile saline and administered IP (10ml/kg) daily dose for 5 days, followed by 5 days of rest and then a second round of daily dosing for 5 days. Hindpaw mechanical hypersensitivity for at least 15 days after.
Human epidermal carcinoma cell line was treated with Paclitaxel, docetaxel,vincristine, vinblastine, colchicine, cisplatin, and mitoxantrone which purchased from Tocris Bioscience.
Used this product in caspase assay.
Determined the optimal dose to identify the chemoresistant population in our cell line. Cells were treated with escalating doses of cisplatin (0.01-100uM) and viability determined 4 days post treatment.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.